Tracey Regan

Since its approval in 1998 to treat metastatic disease, trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive breast cancer.

Targeted Oncology interviewed Cy Stein, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology and deputy director of Clinical Research at City of Hope National Medical Center.

The efficacy and safety of adding the experimental agent brentuximab vedotin (Adcetris) to standard chemotherapy to treat patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) is being evaluated in a randomized, open-label phase II trial.

The efficacy of combining two immunotherapy agents will be assessed in a randomized, double-blind phase III study.

The second-generation TKI dacomitinib, designed to treat NSCLC, is being evaluated in a clinical trial that will measure the drug’s effectiveness as a first-line treatment.